TrialScientific reports2022

The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.

Tsuyoshi Okura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.